List view / Grid view
Duke researchers used a bivalent virus from chicken cells that packaged twice as much protein as a monovalent virus, and vaccinated mice with either the bivalent or monovalent vaccine
Small skin patches with dissolvable microneedles were safe and well-tolerated, generated robust immunity against influenza, could be self-administered by study participants and were strongly preferred over shots.
5 April 2016 | By Victoria White
This recommendation allows a vaccine containing a strain of pandemic potential to be developed and authorised in advance of a pandemic being declared...
7 March 2016 | By Victoria White
MedImmune has received Fast Track designation from the FDA for MEDI8852 for the treatment of patients hospitalised with Type A strain influenza...
3 February 2016 | By Victoria White
The submission seeks an expanded indication for Flulaval Quadrivalent in the US for children six months through 35 months of age...
5 January 2016 | By Victoria White, European Pharmaceutical Review
A number of pharmaceutical companies see great potential in a universal flu vaccine, each hoping they will be the first to gain regulatory approval of their candidates. European Pharmaceutical Review spoke with Gregory Stoloff, CEO of one such company, SEEK, to find out more...
12 November 2015 | By Victoria White
FLU-v is a peptide-based vaccine that stimulates a cytotoxic T lymphocyte and non-neutralising antibody response against influenza. FLU-v may have potential as a cross-protective vaccine for multiple strains of influenza...
4 November 2015 | By Victoria White
ESCMID believes that one vital tool to increase the adoption of flu vaccinations among healthcare professionals is to establish hospital-based league tables throughout Europe...
17 July 2015 | By Victoria White
GSK has begun shipping Flaurix Quadrivalent (flu vaccine) doses to US healthcare providers and expects to begin shipping Flulaval Quadrivalent in August...
14 July 2015 | By Victoria White
The FDA has released the first doses of Sanofi Pasteur’s Fluzone influenza vaccine for shipment for the 2015-2016 influenza season in the US...
6 February 2015 | By Public Health England
Flu vaccination remains important for other strains that still may circulate this winter...
27 October 2014 | By Imaxio
Imaxio announces that it has been awarded funding of EUR 600,000 (USD 772,000) by the French National Research Agency (Agence Nationale de la Recherche, ANR) for the OPTIVAC project 'leveraging On t-cell immune resPonse To Improve influenza VACcines'...
23 September 2014 | By Andrew Lloyd & Associates
A new antigens formulation against pandemic flu (A H1N1 virus) proved six times more effective than other vaccines...
31 July 2014 | By The European Medicines Agency
The European Medicines Agency has released the second module of a new overarching guideline on influenza vaccines for a six-month public consultation...
Influenza viruses are members of the Orthomyxoviridae family and are a major cause of respiratory tract disease in humans and many animal species. There are three influenza virus types that cause human disease: A, B and C. Type A are further subtyped based on the antigenicity of the hemagglutinin (HA)…
